Last --
Change Today 0.00 / 0.00%
Volume 0.0
600196 On Other Exchanges
Symbol
Exchange
600196 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shanghai fosun pharmaceuti-a (600196) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FOSUN PHARMACEUTI-A (600196)

Related News

No related news articles were found.

shanghai fosun pharmaceuti-a (600196) Related Businessweek News

No Related Businessweek News Found

shanghai fosun pharmaceuti-a (600196) Details

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, is engaged in the research and development, manufacture, distribution, and retail sale of pharmaceutical products in Mainland China and internationally. The company offers metabolism and alimentary tract drugs for the treatment of chronic hepatitis B, diabetes, chronic atrophic gastritis and gastralgia, flatulence, anorexia, eructation, and pyrosis; and anti-infection drugs to treat malaria, cefmetazole sodium sensitive bacterial infections, tuberculosis, sensitive gram-positive bacterial infections, and viral pneumonia and upper respiratory tract infections. It also provides cardiovascular and blood system drugs for antithrombotic treatment, ductus dependent congenital heart diseases, hypoxaemia relief, and chronic hepatitis; and the treatment of myocarditis, sinus syndrome, coronary heart disease, cardiomyopathy, arrhythmia, hypertension, microangiopathy, varicose veins syndrome, microcirculatory disorders, hypercholesterolemia, anemia, and chronic renal failure, as well for various dialysis treatments. In addition, the company offers oncology drugs for the treatment of lung, breast, prostate, gastric, colorectal, and nasopharyngeal cancers, as well as malignant pleural mesothelioma; and vaccines for the prevention of influenza. Further, it provides central nervous system drugs; and crude drugs and intermediates. Additionally, the company develops, manufactures, sells, imports, and exports medical equipment; provides healthcare and hospital management services, and consulting services; and manufactures and sells biologic pharmaceutical products. It operates approximately 650 retail pharmacies under For Me Pharmacy and Golden Elephant Pharmacy brands. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China.

17,529 Employees
Last Reported Date: 08/26/14
Founded in 1994

shanghai fosun pharmaceuti-a (600196) Top Compensated Officers

Vice Chairman, Chief Executive Officer, Presi...
Total Annual Compensation: CNY5.0M
Executive Chairman and Chairman of Strategic ...
Total Annual Compensation: CNY6.8M
Supervisor
Total Annual Compensation: CNY1.2M
Supervisor
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

shanghai fosun pharmaceuti-a (600196) Key Developments

Nature's Sunshine Products Inc. and Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. Announce Close of Joint Venture Agreement

Nature's Sunshine Products Inc. announced the closing of its previously announced China joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and private placement transaction of 2.854 million shares of common stock, representing approximately 15% of Nature's Sunshine's outstanding common shares, to Fosun Pharma at a price of $16.19 per share. Aggregate proceeds to Nature's Sunshine were approximately $46.2 million. The joint venture, known as Nature's Sunshine Hong Kong Limited, is 80% owned by Nature's Sunshine and 20% owned by a wholly-owned subsidiary of Fosun Pharma.

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the six months, revenue was RMB 5,502,224,000 compared to RMB 4,473,639,000 a year ago. Profit before tax was 1,338,167,000 against 1,451,090,000 a year ago. Profit attributable to the owners of the parent company was RMB 1,002,015,000 or RMB 0.44 per basic and diluted share compared to RMB 1,053,141,000 or RMB 0.47 per basic and diluted share a year ago. Net cash flow generated from operating activities was RMB 404,000 against RMB 311,000 last year.

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd., Board Meeting, Aug 26, 2014

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd., Board Meeting, Aug 26, 2014. Agenda: To approve the interim results of the company and its subsidiaries for the six months ended June 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600196:CH CNY18.74 CNY -0.04

600196 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bangkok Dusit Medical Services PCL 19.40 THB -0.10
Bumrungrad Hospital PCL 140.00 THB +5.00
Fortis Healthcare Ltd 119.75 INR -0.30
IHH Healthcare Bhd 4.90 MYR +0.02
KPJ Healthcare Bhd 3.86 MYR +0.03
View Industry Companies
 

Industry Analysis

600196

Industry Average

Valuation 600196 Industry Range
Price/Earnings 21.7x
Price/Sales 3.9x
Price/Book 2.8x
Price/Cash Flow 18.3x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI FOSUN PHARMACEUTI-A, please visit www.fosunpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.